Stockscreener 앱 받기
15.55
1.77%
-0.28
시장 영업 전:
15.58
0.03
+0.19%
전일 마감가:
$15.83
열려 있는:
$15.29
하루 거래량:
4.15M
Relative Volume:
0.78
시가총액:
$12.41B
수익:
$220.00K
순이익/손실:
$-1.21B
주가수익비율:
-9.6951
EPS:
-1.6039
순현금흐름:
$-387.48M
1주 성능:
+6.29%
1개월 성능:
-5.47%
6개월 성능:
-30.18%
1년 성능:
-17.07%
1일 변동 폭
$0.00
$0.00
1주일 범위
$14.83
$16.35
52주 변동 폭
$12.07
$29.23
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
15.55 | 12.41B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
535.17 | 135.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
819.09 | 84.33B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
202.63 | 80.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
875.76 | 55.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
382.27 | 43.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2026-08-25 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2026-08-12 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2026-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2026-04-08 | 개시 | Stifel | Buy |
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Summit Expands Ivonescimab Development Into Biliary Tract Cancer - Zacks Investment Research
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential? - Zacks Investment Research
For distant-stage biliary cancer, estimated five-year survival is under 5%. Summit plans a drug-combination trial. - Stock Titan
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma - Investing News Network
A share-increase proposal at Summit Therapeutics (SMMT) would help enable conversion of $2B in preferred stock. - Stock Titan
Accounting chief gets a stock grant at Summit Therapeutics (SMMT), vesting in 2029 if still employed. - Stock Titan
Summit Therapeutics Inc Stock (SMMT) Moved Down by 8.61% on Oct 13: Key Drivers Unveiled - TradingKey
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics - citybiz
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos - Zacks Investment Research
Summit Therapeutics (NasdaqGM:SMMT) Stock Forecast & Analyst Predictions - Simply Wall Street
AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up - Yahoo Finance
Summit Therapeutics Stock Climbs Wednesday: What's Happening? - Benzinga
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - 24/7 Wall St.
Summit Therapeutics secures major AstraZeneca equity partnership - The Globe and Mail
AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - Yahoo Finance
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics - Pharmaceutical Executive
AstraZeneca Invests $2B in Summit for Cancer Drug Dev - Rediff MoneyWiz
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab - Benzinga
Summit Therapeutics Shares Rise 22% After $2 Billion AstraZeneca Investment - Yahoo Finance
Summit Therapeutics Raises $2.0 Billion in Convertible Preferred Private Placement With AstraZeneca - TradingView
AstraZeneca invests $2bn in Summit Therapeutics to develop cancer drug - Business Weekly
Summit snags $2B investment from AstraZeneca, clearing financial overhang - BioSpace
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - Reuters
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Proactive financial news
Summit Therapeutics agrees to US$2B AstraZeneca equity investment - Mugglehead Investment Magazine
AstraZeneca invests $2 billion in Summit Therapeutics By Investing.com - Investing.com
Summit Therapeutics rises after AstraZeneca commits $2B investment - TradingView
AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer - AstraZeneca
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics - Business Wire
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Yahoo Finance UK
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Yahoo Finance
Summit Therapeutics (SMMT) Shows Promising Trial Results but Faces Valuation Challenges - GuruFocus
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics (SMMT) Gains Attention as Phase III Trial Data Boosts Outlook Amid Valuation Challenges - GuruFocus
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com South Africa
Summit Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com
Summit Therapeutics shares gain after Jefferies upgrades stock to Buy - Yahoo Finance
Summit Therapeutics stock surges on Jefferies upgrade to buy By Investing.com - Investing.com Canada
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com Canada
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com UK
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 61.45% Upside - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress - Yahoo Finance
Ivonescimab Demonstrates an Overall Survival Benefit in Advanced NSCLCSummit Therapeutics - Oncodaily
Why Summit Therapeutics (SMMT) Is Up 19.5% After New Ivonescimab Phase III Survival DataAnd What's Next - simplywall.st
Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S. (SMMT) - Seeking Alpha
Why is Summit Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Summit's Ivonescimab Beats Merck's Keytruda on Survival in Chinese Lung Cancer Trial - finance.biggo.com
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug - Barron's
Why Is Summit Therapeutics Stock Soaring Today?Summit Therapeutics (NASDAQ:SMMT) - Benzinga
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - benzinga.com
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 12 '26 |
Buy |
13.12 |
3,810,000 |
49,987,200 |
573,883,879 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Jun 04 '26 |
Buy |
14.60 |
100,000 |
1,460,000 |
25,824,474 |
| Soni Manmeet Singh | COO and CFO |
Jun 04 '26 |
Buy |
14.45 |
50,000 |
722,250 |
3,123,603 |
| Xia Yu | Director |
Oct 21 '25 |
Buy |
18.74 |
533,617 |
9,999,983 |
32,057,147 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
7.55%
0.56%
자본화:
|
볼륨(24시간):